USD 0.35
(2.88%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 41.49 Million USD | -32.38% |
2022 | 56.67 Million USD | 12.61% |
2021 | 50.32 Million USD | 31.73% |
2020 | 38.2 Million USD | -12.43% |
2019 | 43.63 Million USD | 8.57% |
2018 | 40.18 Million USD | -13.56% |
2017 | 46.49 Million USD | -3.32% |
2016 | 48.08 Million USD | 8.17% |
2015 | 44.45 Million USD | 44.34% |
2014 | 30.8 Million USD | 54.32% |
2013 | 19.95 Million USD | 36.03% |
2012 | 14.67 Million USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 10.45 Million USD | 25.26% |
2024 Q2 | 8.83 Million USD | -15.54% |
2023 Q1 | 11.77 Million USD | 1.91% |
2023 Q4 | 8.35 Million USD | -25.14% |
2023 Q3 | 11.15 Million USD | 9.93% |
2023 Q2 | 10.14 Million USD | -13.8% |
2023 FY | 38.32 Million USD | -32.38% |
2022 Q2 | 15.84 Million USD | -0.23% |
2022 Q4 | 11.54 Million USD | -13.76% |
2022 FY | 56.67 Million USD | 12.61% |
2022 Q1 | 15.88 Million USD | 33.53% |
2022 Q3 | 13.39 Million USD | -15.5% |
2021 Q1 | 10.86 Million USD | 25.9% |
2021 Q4 | 11.89 Million USD | -20.26% |
2021 Q3 | 14.92 Million USD | 18.01% |
2021 FY | 50.32 Million USD | 31.73% |
2021 Q2 | 12.64 Million USD | 16.33% |
2020 FY | 38.2 Million USD | -12.43% |
2020 Q1 | 11.43 Million USD | -3.31% |
2020 Q2 | 9.09 Million USD | -20.5% |
2020 Q3 | 9.04 Million USD | -0.47% |
2020 Q4 | 8.63 Million USD | -4.6% |
2019 Q3 | 10.07 Million USD | -6.42% |
2019 FY | 43.63 Million USD | 8.57% |
2019 Q4 | 11.82 Million USD | 17.34% |
2019 Q2 | 10.77 Million USD | -1.7% |
2019 Q1 | 10.95 Million USD | 12.31% |
2018 Q3 | 8.59 Million USD | -24.31% |
2018 FY | 40.18 Million USD | -13.56% |
2018 Q1 | 10.47 Million USD | 7.74% |
2018 Q2 | 11.36 Million USD | 8.47% |
2018 Q4 | 9.75 Million USD | 13.46% |
2017 FY | 46.49 Million USD | -3.32% |
2017 Q1 | 12.45 Million USD | 6.98% |
2017 Q2 | 12.87 Million USD | 3.31% |
2017 Q3 | 11.43 Million USD | -11.13% |
2017 Q4 | 9.72 Million USD | -15.02% |
2016 Q1 | 12.79 Million USD | 9.85% |
2016 Q4 | 11.64 Million USD | 4.59% |
2016 Q3 | 11.13 Million USD | -11.01% |
2016 Q2 | 12.51 Million USD | -2.2% |
2016 FY | 48.08 Million USD | 8.17% |
2015 Q4 | 11.64 Million USD | 2.29% |
2015 Q2 | 11.08 Million USD | 7.28% |
2015 Q1 | 10.33 Million USD | 15.4% |
2015 FY | 44.45 Million USD | 44.34% |
2015 Q3 | 11.38 Million USD | 2.68% |
2014 Q1 | 6.9 Million USD | 21.3% |
2014 Q3 | 7.78 Million USD | 8.92% |
2014 Q4 | 8.95 Million USD | 15.03% |
2014 FY | 30.8 Million USD | 54.32% |
2014 Q2 | 7.14 Million USD | 3.5% |
2013 Q4 | 5.69 Million USD | 22.9% |
2013 FY | 19.95 Million USD | 36.03% |
2013 Q1 | 4.6 Million USD | 0.0% |
2013 Q2 | 5.03 Million USD | 9.35% |
2013 Q3 | 4.63 Million USD | -7.89% |
2012 FY | 14.67 Million USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Bionano Genomics, Inc. | 148.99 Million USD | 72.15% |
Prenetics Global Limited | 60.73 Million USD | 31.682% |
Star Equity Holdings, Inc. | 16.27 Million USD | -155.002% |
CareDx, Inc | 277.76 Million USD | 85.062% |
Exact Sciences Corporation | 2.06 Billion USD | 97.986% |
Exagen Inc. | 52.29 Million USD | 20.651% |
Inotiv, Inc. | 246.9 Million USD | 83.194% |
Guardant Health, Inc. | 901.62 Million USD | 95.398% |
Biodesix, Inc. | 77.41 Million USD | 46.403% |
BioNexus Gene Lab Corp. | 3.92 Million USD | -957.688% |
Precipio, Inc. | 13.63 Million USD | -204.253% |
iSpecimen Inc. | 16.27 Million USD | -154.92% |
Natera, Inc. | 938.98 Million USD | 95.581% |
Aspira Women's Health Inc. | 24.11 Million USD | -72.074% |
Standard BioTools Inc. | 113.48 Million USD | 63.438% |
23andMe Holding Co. | 420.73 Million USD | 90.138% |
Castle Biosciences, Inc. | 242.78 Million USD | 82.909% |
Personalis, Inc. | 128.14 Million USD | 67.619% |
Aclaris Therapeutics, Inc. | 110.52 Million USD | 62.457% |
Applied DNA Sciences, Inc. | 16.48 Million USD | -151.681% |
OpGen, Inc. | 30.65 Million USD | -35.345% |
Myriad Genetics, Inc. | 600.1 Million USD | 93.085% |
ICON Public Limited Company | 755.64 Million USD | 94.509% |
NeoGenomics, Inc. | 341.25 Million USD | 87.841% |
Star Equity Holdings, Inc. | 16.27 Million USD | -155.002% |
IDEXX Laboratories, Inc. | 1.09 Billion USD | 96.203% |
RadNet, Inc. | 268.87 Million USD | 84.568% |
MDxHealth SA | 71.25 Million USD | 41.768% |
Psychemedics Corporation | 11.33 Million USD | -266.102% |
Illumina, Inc. | 3.81 Billion USD | 98.912% |
Check-Cap Ltd. | 19.28 Million USD | -115.14% |
Twist Bioscience Corporation | 354.18 Million USD | 88.284% |
DarioHealth Corp. | 62.17 Million USD | 33.26% |
Fulgent Genetics, Inc. | 171.9 Million USD | 75.862% |
Sera Prognostics, Inc. | 39.91 Million USD | -3.951% |
ENDRA Life Sciences Inc. | 10.52 Million USD | -294.402% |
OPKO Health, Inc. | 574.68 Million USD | 92.78% |
Medpace Holdings, Inc. | 187.68 Million USD | 77.891% |
Neogen Corporation | 405.23 Million USD | 89.761% |
Intelligent Bio Solutions Inc. | 11.7 Million USD | -254.383% |
Prenetics Global Limited | 60.73 Million USD | 31.682% |
Mainz Biomed B.V. | 27.15 Million USD | -52.808% |
bioAffinity Technologies, Inc. | 8.76 Million USD | -373.414% |
Trinity Biotech plc | 46.49 Million USD | 10.756% |
Neuronetics, Inc. | 82.25 Million USD | 49.557% |
Sotera Health Company | 300.46 Million USD | 86.19% |
bioAffinity Technologies, Inc. | 8.76 Million USD | -373.414% |